Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) hit a new 52-week high during trading on Monday . The company traded as high as $27.90 and last traded at $27.82, with a volume of 198,411 shares trading hands. The stock had previously closed at $26.96.

A number of analysts have commented on the stock. Leerink Swann restated a “buy” rating on shares of Theravance Biopharma in a research note on Saturday, June 4th. Bank of America Corp. lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 5th. Guggenheim assumed coverage on shares of Theravance Biopharma in a research note on Monday, June 20th. They set a “buy” rating and a $30.00 price target for the company. Finally, Zacks Investment Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Theravance Biopharma currently has an average rating of “Hold” and a consensus target price of $29.00.

The stock’s market capitalization is $1.32 billion. The stock has a 50 day moving average of $24.21 and a 200-day moving average of $20.79.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by $0.01. Equities research analysts expect that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current year.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.